Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have demonstrated cardio-renal benefits in large randomized controlled trials in people with diabetic kidney disease (DKD) and residual albuminuria all on renin angiotensin system (RAS) inhibition (1–3). Here, SLC5A2 is linked to diabetic kidney disease.